Chan, B. A., Peters, S., Leon, L., Yamada, T., Makani, N. S., Huang, W., Spyratos, D., Roubec, J., Reinmuth, N., Sacher, A. G., Spira, A. I., Singhal, N., Takeuchi, S., Murciano-Goroff, Y. R., Zhou, Y., Fink, A. A., Merced, A., Willard, M. D., Grul, C. M. V., Johnson, M. L. (2026). First-line (1L) olomorasib + pembrolizumab in patients with
                    <i>KRAS</i>
                    G12C–mutant advanced NSCLC, and PD-L1 expression 0-49%, from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8628